關(guān)鍵詞

CAR-T 溶酶體跨膜蛋白 免疫 基質(zhì)細(xì)胞 鉑 特異性抗體 ChatGPT 酪氨酸激酶抑制劑 納米抗體

??

#今日行業(yè)熱點(diǎn)#

①Cell：Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity

疫苗增強(qiáng)的CAR-T與宿主免疫相互作用以排斥具有抗原異質(zhì)性的腫瘤

DOI: 10.1016/j.cell.2023.06.002

②Cell：TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry

發(fā)現(xiàn)：溶酶體跨膜蛋白TMEM106B是介導(dǎo)非依賴性ACE2的SARS-CoV-2細(xì)胞進(jìn)入的受體

DOI: 10.1016/j.cell.2023.06.005

③Cancer Cell：Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression

分析：胃腺癌進(jìn)展過(guò)程中免疫和基質(zhì)細(xì)胞狀態(tài)和生態(tài)型的演變

DOI: 10.1016/j.ccell.2023.06.005

④Cell Chemical Biology：Inhibition of nucleolar transcription by oxaliplatin involves ATM/ATR kinase signaling

奧沙利鉑誘導(dǎo)了一個(gè)獨(dú)特的ATM和ATR信號(hào)通路抑制核仁轉(zhuǎn)錄

DOI: 10.1016/j.chembiol.2023.06.010

⑤Cell Chemical Biology：Novel Frizzled-specific antibody-based Wnt mimetics and Wnt superagonists selectively activate WNT/β-catenin signaling in target tissues

基于新型卷曲特異性抗體的WNT模擬劑和WNT超激動(dòng)劑選擇性地激活靶組織中的WNT/β-catenin信號(hào)通路

DOI: 10.1016/j.chembiol.2023.06.006

⑥Trends in Cancer：Pearls and pitfalls of ChatGPT in medical oncology

見(jiàn)解：ChatGPT對(duì)醫(yī)學(xué)和腫瘤學(xué)的價(jià)值及潛在陷阱

DOI: 10.1016/j.trecan.2023.06.007

⑦高活性小分子RET酪氨酸激酶抑制劑SY-5007片用于RET融合晚期非小細(xì)胞肺癌（NSCLC）的Ⅲ期臨床即將啟動(dòng)

⑧靶向CDH3的抗體偶聯(lián)藥物BC3195在國(guó)內(nèi)開(kāi)展的用于局部晚期或轉(zhuǎn)移性實(shí)體瘤的Ⅰa/Ⅰb期臨床完成首例受試者給藥

⑨EGFR抑制劑BDTX-1535用于EGFR突變非小細(xì)胞肺癌（NSCLC）的Ⅰ期臨床獲積極結(jié)果

⑩抗GPC3/TCR納米抗體（VHH）SAR444200獲國(guó)家藥監(jiān)局臨床許可，擬開(kāi)發(fā)用于GPC3陽(yáng)性晚期實(shí)體瘤

科學(xué)探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！